NCT02700022终止1 期
A Phase I/Ib Study of Alisertib Plus R-EPOCH for Treatment of Myc-Positive Aggressive B-Cell Lymphomas
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 1
- 试验地点
- 2
- 主要终点
- Maximum tolerated dose (MTD)
研究概览
简要总结
This phase I/Ib study is designed to establish the safety and maximum tolerated dose (MTD, which will also be the recommended phase II dose (RP2D)) of the aurora kinase A inhibitor alisertib when combined with dose-adjusted (DA)-R-EPOCH (rituximab, etoposide, doxorubicin, vincristine, cyclophosphamide and prednisone) in patients with CD20-positive diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma or Burkitt lymphoma positive for Myc gene rearrangement (Myc+). Filgrastim or peg-filgrastim is also included with each cycle of R-EPOCH. Once we identify the MTD, an expansion cohort limited to the Myc+ DLBCL population will be opened to further characterize clinical activity and safety.
Secondary objectives include estimates of complete response rate (CR) and progression free survival (PFS). We will also explore for associations between baseline kinome signatures and/or RNA sequencing and CR, and identify differential kinome and transcriptome prior to and during treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥18 y/o (no upper age limit)
- •ECOG PS ≤2
- •Disease - Histologically or cytologically documented newly diagnosed (stages II, III or IV) Myc-positive DLBCL, transformed follicular lymphoma, or high-grade unclassifiable with features intermediate between DLBCL and Burkitt lymphoma
- •Myc Positive lymphoma is defined by:
- •Positive for Myc gene rearrangement by fluorescence in-situ hybridization (FISH) involving various breakpoints (e.g. 8-14, 8-22 and 2-8) AND concurrent gene rearrangements in bcl-2 and/or bcl-6 by FISH OR
- •Myc and Bcl-2 overexpression defined by > 40% Myc and > 70% Bcl-2 expression by IHC. Patients may enroll in the study based on the local laboratory evaluation, but these should be confirmed by the UNC Hematopathology Laboratory retrospectively
- •Positive for CD20 via immunophenotyping
- •Prior Treatment: Previously untreated or who received a maximum of one cycle of combination chemotherapy (i.e. R-CHOP, R-EPOCH, or R-hyperCVAD) within 4 weeks of study entry except patients who require dose reduction after the first cycle of off-study R-EPOCH.
- •Measurable disease as assessed by 2 dimensional measurements by CT (≥ 1.5 cm).
- •Adequate organ function as demonstrated by:
- •Bone marrow function (without platelet transfusion or myeloid growth factor support within two weeks of screening) as demonstrated by:
- •Hemoglobin ≥ 8 g/dL
- •Absolute neutrophil count (ANC) ≥ 1,000 cells/mm3
- •Platelet count ≥75,000/mm3
- •And hepatic and renal function as demonstrated by:
- •Aspartate aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤2.5 x upper limit of normal (ULN); ALT and AST up to 5 x ULN if liver metastases present
- •Total serum bilirubin ≤1.5 x ULN
- •Serum creatinine ≤1.5 x ULN or CrCl of ≥ 30
- •Adequate renal function as defined by: Calculated creatinine clearance must be ≥ 30 mL/minute based on Cockcroft-Gault formula
- •Documented negative serologic testing for human immunodeficiency virus (HIV), hepatitis B (unless serologically positive due to prior vaccination), and hepatitis C within the year prior to enrollment (note: for guidance in defining active infection for hepatitis B, please refer to the WHO guidelines. (World Health Organization, Global Alert and Response (GAR), Hepatitis B (who.int/csr/disease/hepatitis/ whocdscsrlyo20022/en/index4.html)
- •Patient agrees to consume no more than 1 standard unit of alcohol per day during the study and for 30 days from the last dose of alisertib. A standard unit of alcohol is defined as a 12 oz beer (350 mL), 1.5 oz (45 mL) of 80-proof alcohol, or one 6-oz (175 mL) glass of wine.
- •Women of childbearing potential (WOCBP) must have negative pregnancy test within 7 days prior to D1 of treatment
- •Female subjects must be:
- •Post-menopausal for at least one year before the screening visit, or
- •Surgically sterilized, or
- •Willing to use an acceptable method of birth control (ie, a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study.
- •Male subject, even if surgically sterilized (ie, status post-vasectomy), agrees to:
- •Use an acceptable method for contraception (effective barrier contraception or:
- •Completely abstain from heterosexual intercourse) during the entire study treatment period through 4 months after the last dose of alisertib.
- •Ability to swallow oral medications
- •As determined by the enrolling physician or protocol designee, ability of the patient to understand and comply with study procedures for the entire length of the study
- •Sufficient data to calculate the International Prognostic Index (IPI) score at baseline:
- •Stage of Disease
- •ECOG performance status
- •number of extranodal sites
- •Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.
- •Adequate left ventricular function with ejection fraction ≥ 40% by echocardiogram or MUGA scan.
- •Exclusion Criteria
- •CNS involvement of DLBCL
- •Major surgery within 4 weeks prior to entry
- •Receiving any other concurrent cytotoxic, biologic agent(s) or investigational agent ; NOTE: Concurrent intrathecal chemotherapy for CNS prophylaxis allowed per institutional standards
- •Receipt of investigational drugs within 14 days before D1 of alisertib
- •Prior administration of an Aurora A kinase-targeted agent, including alisertib
- •Patients with a "currently active" second malignancy other than non-melanoma skin cancers, non-invasive bladder cancer, "low risk" adenocarcinoma of the prostate and carcinoma in situ of the cervix. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are free of disease for ≥ 3 years.
- •Treatment with clinically significant enzyme inducers, such as the enzyme-inducing antiepileptic drugs phenytoin, carbamazepine or phenobarbital, or rifampin, rifabutin, rifapentine or St. John's wort within 14 days prior to the first dose of alisertib and during the study.
- •Radiation therapy to more than 25% of the bone marrow (note: whole pelvic radiation is considered to be over 25%)
- •Prior allogeneic bone marrow or organ transplantation
- •Known GI disease or GI procedures that could interfere with the oral absorption or tolerance of alisertib; examples include, but are not limited to partial gastrectomy, history of small intestine surgery, and celiac disease
- •Known history of uncontrolled sleep apnea syndrome and other conditions that could result in excessive daytime sleepiness, such as severe chronic obstructive pulmonary disease; requirement for supplemental oxygen
- •Requirement for constant administration of proton pump inhibitor from 5 days prior to D1 of alisertib, and/or requirement for constant administration of H2 antagonist, or pancreatic enzymes; intermittent uses of antacids or H2 antagonists are allowed
- 另有 9 项未显示
排除标准
- 未提供
研究组 & 干预措施
Alisertib combined with R-EPOCH
Experimental
Dose escalation will take place within cohorts. Subjects will receive alisertib tablets twice daily in combination with R-EPOCH chemotherapy on days 1 through 5 of each 21-day cycle. The treatment will be given in 6 cycles. The first 3 patients to be enrolled will receive a 20 milligram (mg) dose of alisertib. The dose of alisertib will be increased or decreased as more subjects enter the study. Each dose level will be evaluated for safety and tolerability before the next higher dose is given. The dose levels will be modified until the maximum tolerated dose (MTD) is reached. Once the MTD has been established, enrollment into that cohort will continue with up to a maximum of 24 patients total enrolled into the study.
干预措施: Alisertib (Drug)
结局指标
主要结局
Maximum tolerated dose (MTD)
时间窗: 2 years
次要结局
- Progression free survival(from day 1 of treatment until up to 2 years after treatment or death, whichever occurs first)
- Toxicity(from day 1 of treatment until up to 2 years after treatment)
- Rate of Response(from day 1 of treatment until up to 2 years after treatment)
研究者
研究点 (2)
Loading locations...
相似试验
撤回
1 期
Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid MalignanciesCD30-positive LymphomaCD30-positive Solid TumorNCT02780011Eric Bernicker, MD
终止
1 期
Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid TumorsAdvanced Solid TumorsOvarian CancerSmall Cell Lung CancerNCT02367352Millennium Pharmaceuticals, Inc.9
已完成
1 期
Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by SurgeryEstrogen Receptor PositiveProgesterone Receptor PositiveRecurrent Breast CarcinomaStage IIIB Breast CancerStage IIIC Breast CancerStage IV Breast CancerNCT02219789Mayo Clinic10
已完成
1 期
Phase I/Ib Multiple Ascending Dose Study in ChinaMetastatic Solid TumorsNCT03523390Merck KGaA, Darmstadt, Germany24
撤回
1 期
Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated MalignanciesMalignant Neoplasms of Digestive OrgansMalignant Neoplasms of Female Genital OrgansMalignant Neoplasms of Lip Oral Cavity and PharynxMalignant Neoplasms of Male Genital OrgansNCT02812056M.D. Anderson Cancer Center